THE CONFERENCE

Pricing and Market Access

• Regulation & Reimbursement
• Investment & funding strategies
• Clinical development and product release

Gene Editing

• Delivering autologous and allogenic CAR-T
• Moving from phase II – phase III
• Clinical development
• Autologous
• Allogenic
• Scaling up production
• Moving beyond CAR-T towards gene editing and microbiome treatments

 

Immunotherapy

• Ensuring clinical success and safety
• Immuno-oncology
• Regulation, reimbursement and market access
• Non-oncology

Cell Therapy

• Regulation
• Mechanism of action
• Stem cells and regenerative medicine
• iPSCs vs MSCs

 

Research & Development

• New clinical data Safety and efficacy
• New methods and strategies for success

 

Gene Therapy

• New preclinical and clinical data
• Safety and efficacy
• New methods and strategies for success

 

Stem Cells & Regen Med

• Expansion and engraftment
• Donation and Education
• Banking
• From lab to clinic
• Haplo vs cord blood

 

Gene Modified Cell Therapy 

• Facility design
• Successful tech transfer
• Keeping a clean room
• De-risking supply chain

 

Viral Vector Manufacture

• Process development: Scale up and scale out
• GMP Manufacturing & formulation of finished product
• Non-clinical development programmes

 

Patient Delivery 

• Sample collection, handling and logistics
• Regulation
• Product distribution
• Cryo-shipping strategies
• Manufacturing automation and cell therapy
• Reimbursement and integrated care

 

Pitch and Partner

 

 

Innovation Zone